<h4>&bull; Excessive bleeding after birth, also known as postpartum haemorrhage (PPH), is the leading direct cause of maternal mortality worldwide,¹ causing approximately 70,000 deaths each year¹ &ndash; 99% of which occur in low- and lower-middle income countries²<br />
<br />
&bull; Carbetocin Ferring is the first medicine approved under the new Swissmedic and Marketing Authorisation for Global Health Products (MAGHP) procedure,³ which aims to build capacity and speed up access to essential medicines in low- and middle-income countries⁴<br />
<br />
&bull; Ferring developed this heat-stable formulation of carbetocin to specifically address limitations in refrigeration and cold-chain transport of PPH medications in low- and lower-middle income countries5<br />
<br />
&bull; Heat-stable carbetocin is recommended for PPH prevention in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics⁶</h4>